Compare IFN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFN | VALN |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.7M | 495.5M |
| IPO Year | 1994 | 2021 |
| Metric | IFN | VALN |
|---|---|---|
| Price | $11.61 | $5.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 154.1K | 18.4K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.72 | $5.04 |
| 52 Week High | $16.18 | $12.25 |
| Indicator | IFN | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 39.11 |
| Support Level | $11.40 | $5.10 |
| Resistance Level | $11.79 | $5.52 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 46.07 | 14.00 |
India Fund Inc is a non-diversified closed-end management investment company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.